Investigational drug · Phase 3
MK-7240
Also called: PRA023, Tulisokibart
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
15
Any phase or sponsor naming "MK-7240"
First trial start
2022
Mar 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-7240", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Psoriatic Arthritis
- Crohn's Disease
- Diffuse Cutaneous Systemic Sclerosis
- Interstitial Lung Disease
- Radiographic Axial Spondyloarthritis
- Pulmonary Sarcoidosis
- Hidradenitis Suppurativa
- Arthritis, Rheumatoid
- Crohn Disease
Approved drugs for the same conditions: Psoriatic arthritis · Crohn's disease · Ulcerative colitis · Ankylosing spondylitis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-7240" as an intervention, largest first.
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06430801 · 1,200 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 30, 2028
Drug: IV Tulisokibart; SC Tulisokibart · For: Crohn's Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 499 sites in all
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06052059 · 1,109 participants · Start Oct 25, 2023 · Primary completion Aug 12, 2026
Drug: IV Tulisokibart; IV Placebo and 2 more · For: Ulcerative Colitis
Sites: Dothan, Alabama; Fairhope, Alabama; Litchfield Park, Arizona · 476 sites in all
- A Study of MK-7240 in Healthy Participants (MK-7240-009)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07405177 · 330 participants · Start Mar 5, 2026 · Primary completion Sep 19, 2026
Drug: Tulisokibart Form 1; Tulisokibart Form 2 · For: Healthy
Sites: Brisbane, Australia; Melbourne, Australia
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07133633 · 315 participants (planned) · Start Sep 26, 2025 · Primary completion Mar 29, 2027
Drug: Tulisokibart; Placebo · For: Radiographic Axial Spondyloarthritis
Sites: Chandler, Arizona; Flagstaff, Arizona; Gilbert, Arizona · 108 sites in all
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07176390 · 185 participants · Start Oct 8, 2025 · Primary completion Sep 7, 2026
Drug: Tulisokibart; Placebo and 1 more · For: Arthritis, Rheumatoid
Sites: Glendale, Arizona; Mesa, Arizona; La Palma, California · 61 sites in all
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)Pivotal-lookingCompleted
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT04996797 · 178 participants · Start Jul 14, 2021 · Primary completion Jun 6, 2023
Drug: Tulisokibart · For: Ulcerative Colitis
Sites: Mobile, Alabama; Phoenix, Arizona; Sun City, Arizona · 88 sites in all
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07867938 · 158 participants (planned) · Start Nov 3, 2026 · Primary completion Oct 5, 2029
Drug: Tulisokibart; Background prednisone therapy · For: Pulmonary Sarcoidosis
Sites: Shreveport, Louisiana
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)Pivotal-lookingActive, not recruiting
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT05270668 · 154 participants · Start Mar 29, 2022 · Primary completion Apr 16, 2026
Drug: Tulisokibart; Placebo · For: Diffuse Cutaneous Systemic Sclerosis; Interstitial Lung Disease
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 95 sites in all
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06956235 · 149 participants · Start Jun 9, 2025 · Primary completion Apr 2, 2026
Drug: Tulisokibart; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Rogers, Arkansas · 68 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TL1A-DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting.
Tsuruta K, Yoshioka S, Takedatsu H · Kurume Med J 2026
- Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.
Quraishi MN, Jairath V, Al-Bawardy B · Inflamm Bowel Dis 2026
- Tumor necrosis factor-like cytokine 1ߙA antagonists for inflammatory bowel disease: A systematic review and meta-analysis.
Paudel MS, Sharma V, Bhattarai K, et al. · Indian J Gastroenterol 2026
- TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials.
Choi JG, Gong EJ, Bang CS, et al. · Saudi J Gastroenterol 2026
- Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.
Gupte D, Suthar NR, MacDonald JK, et al. · Paediatr Drugs 2026
- Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
Goyal MK, Srivastava H, Sehgal T, et al. · Aliment Pharmacol Ther 2026
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.